Christophe Schmitt - Pharmaceutical Division, F. Hoffmann-La Roche, Ltd.

基本信息

浏览量：24

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 72 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Long-term Outcomes with Emicizumab in Hemophilia A Without Inhibitors: Results from the HAVEN 3 and 4 Studies

Johnny Mahlangu,Victor Jimenez-Yuste,Giuliana Ventriglia,Markus Niggli, Simona Barlera,Cedric Hermans,Michaela Lehle,Pratima Chowdary, Lyle Jew,Jerzy Windyga,Laurent Frenzel,Christophe Schmitt,Giancarlo Castaman,Steven W. Pipe

Research and Practice in Thrombosis and Haemostasispp.102364-102364, (2024)

引用0浏览0WOS引用

Emicizumab Prophylaxis in Infants with Hemophilia A (HAVEN 7): Primary Analysis of a Phase 3b Open-Label Trial

Steven W. Pipe,Peter Collins,Christophe Dhalluin,Gili Kenet,Christophe Schmitt,Muriel Buri,Victor Jimenez-Yuste,Flora Peyvandi,Guy Young,Johannes Oldenburg,Maria Elisa Mancuso,Kaan Kavakli,Anna Kiialainen, Sonia Deb,Markus Niggli,Tiffany Chang,Michaela Lehle,Karin Fijnvandraat

BLOODno. 14 (2024): 1355-1364

引用0浏览0WOS引用

Application of Systems Biology to Identify Pharmacological Mechanisms of Thrombotic Microangiopathy Evoked by Combined Activated Prothrombin Complex Concentrate and Emicizumab

Raquel Valls,Jonathan Wagg,Ido Paz-Priel,Gabriel Man,Laura Artigas, Georges Jaccard,Mireia Coma,Christophe Schmitt

Scientific reportsno. 1 (2023)

引用2浏览0WOSNATURE引用

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Anna Kiialainen,Steven Pipe,Karin Fijnvandraat,Gili Kenet,Christophe Schmitt,Muriel Buri,Víctor Jiménez-Yuste,Johannes Oldenburg,Maria Elisa Mancuso,Christophe Dhalluin,Michaela Lehle,Peter Collins

Blood (2023): 1238

引用0浏览0引用

Clinical Pharmacology of Emicizumab for the Treatment of Hemophilia A

Koichiro Yoneyama,Christophe Schmitt,Agnes Portron,Anna Kiialainen,Naoki Kotani,Felix Jaminion,Sylvie Retout,Joanne Adamkewicz

Expert review of clinical pharmacologyno. 9 (2023): 775-790

引用0浏览0WOS引用

Pharmacokinetics and Coagulation Biomarkers in Children and Adults with Hemophilia A Receiving Emicizumab Prophylaxis Every 1, 2, or 4 Weeks

Anna Kiialainen,Joanne I. Adamkewicz,Claire Petry,Johannes Oldenburg,Steven W. Pipe,Guy Young,Johnny Mahlangu,Michaela Lehle,Markus Niggli,Giancarlo Castaman,Victor Jimenez-Yuste,Midori Shima,Claude Negrier,Christophe Schmitt

Research and practice in thrombosis and haemostasisno. 1 (2023): 102306-102306

引用0浏览0WOS引用

Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A Without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

J. Oldenburg,Cédric Hermans,C Negrier,Michaela Lehle,Pratima Chowdary,Olivier Catalani,Víctor Jiménez‐Yuste,Christophe Schmitt,Giuliana Ventriglia,Jerzy Windyga,Anna Kiialainen,R. d'Oiron,Paul Moorehead, S Koparkar,Vanda Teodoro, D A Shapiro

Hämostaseologie（2023）

引用9浏览0引用

Emicizumab for the treatment of infants with severe hemophilia a: interim analysis of haven 7

Steven Pipe,Peter Collins,Christophe Dhalluin,Gili Kenet,Christophe Schmitt,Muriel Buri,Victor Jimenez-Yuste,Flora Peyvandi,Guy Young,Johannes Oldenburg, Maria ElisaMancuso,Anna Kiialainen,Tiffany Chang,Michaela Lehle,Karin Fijnvandraat

PEDIATRIC BLOOD & CANCER (2023): S7-S7

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn